Arbutus Biopharma Corp. has divulged programmed cell death protein 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, hepatitis B and hepatitis D infections.
Hanmi Holdings Co. Ltd. has identified serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) inhibitors described as potentially useful for the treatment of cancer.
Ariel Scientific Innovations Ltd. has synthesized microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer.
In what represents just the company’s fourth PCT filing, San Jose, Calif.-based Squirrel Corp. seeks protection for systems for electroporation or pulsed field ablation (PFA) treatment of soft tissue tumors.
IFM Due Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to a stimulator of interferon genes protein (STING; TMEM173)-targeting moiety through a linker.
Kaken Pharmaceutical Co. Ltd. has synthesized signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary disease, atopic dermatitis, nasal polyps, bullous pemphigoid, prurigo and urticaria, among others.
New York University has disclosed RAGE receptor antagonists reported to be useful for the treatment of cancer, SARS-CoV-2 infection (COVID-19), diabetic complications, ischemia reperfusion injury, neurodegeneration, obesity, and cardiovascular and inflammatory disorders, among others.
RSS
